VIMOVO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vimovo, and what generic alternatives are available?
Vimovo is a drug marketed by Horizon and is included in one NDA.
The generic ingredient in VIMOVO is esomeprazole magnesium; naproxen. There are seventy-four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the esomeprazole magnesium; naproxen profile page.
Summary for VIMOVO
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Clinical Trials: | 11 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for VIMOVO |
Drug Sales Revenues: | Drug sales revenues for VIMOVO |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIMOVO |
What excipients (inactive ingredients) are in VIMOVO? | VIMOVO excipients list |
DailyMed Link: | VIMOVO at DailyMed |
![VIMOVO drug patent expirations Drug patent expirations by year for VIMOVO](/p/graph/s/t/VIMOVO-patent-expirations.png)
![Drug Prices for VIMOVO](/p/graph/drug-price/VIMOVO.png)
![Drug Sales Revenue Trends for VIMOVO](/p/graph/drug-sales-revenues/VIMOVO.png)
Recent Clinical Trials for VIMOVO
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
EMS | Phase 3 |
Hanyang University Seoul Hospital | Phase 2 |
Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 4 |
Pharmacology for VIMOVO
Anatomical Therapeutic Chemical (ATC) Classes for VIMOVO
Paragraph IV (Patent) Challenges for VIMOVO
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
VIMOVO | Delayed-release Tablets | esomeprazole magnesium; naproxen | 375 mg/20 mg and 500 mg/20 mg | 022511 | 1 | 2010-11-05 |
US Patents and Regulatory Information for VIMOVO
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIMOVO
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIMOVO
See the table below for patents covering VIMOVO around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 100337274 | ⤷ Sign Up | |
Estonia | 9900550 | ⤷ Sign Up | |
Hungary | 225987 | NOVEL FORM OF S-OMEPRAZOLE | ⤷ Sign Up |
Argentina | 059589 | PROCESO PARA LA PREPARACION DE SAL DE MAGNESIO DE TRIHIDRATO DE S-OMEPRAZOL, SAL DE POTASIO DE S-OMEPRAZOL INTERMEDIARIA Y PROCESO PARA PREPARARLA | ⤷ Sign Up |
Austria | 239011 | ⤷ Sign Up | |
Japan | 2004043494 | METHOD FOR PRODUCING NEW COMPOUND | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VIMOVO
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1411900 | 132012902015795 | Italy | ⤷ Sign Up | PRODUCT NAME: NAPROSSENE E ESOMEPRAZOLO SALE DI MAGNESIO TRIIDRATO(VIMOVO); AUTHORISATION NUMBER(S) AND DATE(S): PL 17901/0263-0001, 20101105;DA 40611016/M A 40611129/M, 20110808 |
0984957 | 430 | Finland | ⤷ Sign Up | |
1411900 | 1190013-1 | Sweden | ⤷ Sign Up | PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105 |
0124495 | SPC/GB01/006 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727 |
1411900 | 122012000052 | Germany | ⤷ Sign Up | PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105 |
1020461 | C300482 | Netherlands | ⤷ Sign Up | PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20101105 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |